← LeaderboardsInvestigatorsiAttributed = a PI's even-split share of each grant — a $1M grant with 2 PIs counts $500K each.
Pandomedx, Inc.
Davis, CA
$1,804,305
Total funding
2
Grants
Funding over time
peak $754.3K · FY2016–19$1M$750K$500K$250K$0
'16
'17
'18
'19
Funding mix
By agency
NIH$1,804,305 · 2
By mechanism
R44$1,504,319 · 1
R43$299,986 · 1
Investigators at Pandomedx, Inc.
InvestigatorsiAttributed = a PI's even-split share of each grant — a $1M grant with 2 PIs counts $500K each.
Exposure= the full size of every grant they're on ($1M each).
Rising Stars
First grant in the last 5 yrs
Not enough data
Emerging Leaders
6–10 yrs in
Not enough data
All-Time
Most funded here, all years
Largest grants
A Phase II trial of abiraterone in combination with PDMX1001 in enzalutamide-resistant prostate cancer$754,319
R44 · FY2018 · CA
A Phase II trial of abiraterone in combination with PDMX1001 in enzalutamide-resistant prostate cancer$750,000
R44 · FY2019 · CA
A Phase Ib clinical trial with niclosamide plus abiraterone for Castration Resistant Prostate Cancer (CRPC)$299,986
R43 · FY2016 · CA